Published in J Intensive Care Med on December 02, 2008
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient | NCT04105400
Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care (2013) 1.44
Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods (2013) 0.93
Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis (2009) 0.92
Novel biomarkers to detect infection in revision hip and knee arthroplasties. Clin Orthop Relat Res (2013) 0.91
Clinical application of sepsis biomarkers. J Anesth (2012) 0.90
Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial. PLoS One (2016) 0.90
Use of a Combination Biomarker Algorithm To Identify Medical Intensive Care Unit Patients with Suspected Sepsis at Very Low Likelihood of Bacterial Infection. Antimicrob Agents Chemother (2015) 0.83
Procalcitonin versus C-reactive protein: Usefulness as biomarker of sepsis in ICU patient. Int J Crit Illn Inj Sci (2014) 0.83
CRISPLD2 is expressed at low levels during septic shock and is associated with procalcitonin. PLoS One (2013) 0.82
Clinical Usefulness of Procalcitonin and C-Reactive Protein as Outcome Predictors in Critically Ill Patients with Severe Sepsis and Septic Shock. PLoS One (2015) 0.78
Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers? Int J Endocrinol Metab (2014) 0.76
Can serum procalcitonin measurement help monitor the treatment of acute bacterial meningitis? A prospective study. Caspian J Intern Med (2012) 0.75
Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis. Springerplus (2016) 0.75
High serum trypsin levels and the -409 T/T genotype of PRSS1 gene are susceptible to neonatal sepsis. Inflammation (2014) 0.75
Procalcitonin as an early diagnostic and monitoring tool in urosepsis following percutaneous nephrolithotomy. Urolithiasis (2014) 0.75
Early monitoring of ventriculostomy-related infections with procalcitonin in patients with ventricular drains. J Clin Monit Comput (2015) 0.75
The prognostic value of procalcitonin, C-reactive protein and cholesterol in patients with an infection and multiple organ dysfunction. Korean J Anesthesiol (2017) 0.75
Intracellular pH. Physiol Rev (1981) 16.27
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Intracellular pH and intracellular buffering power of the cat brain. Am J Physiol (1965) 2.47
Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest (1979) 2.42
L-arginine pathway in the sepsis syndrome. Crit Care Med (1993) 2.37
Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation (1995) 2.36
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth (2002) 2.06
Intracellular pH and buffering power of rat muscle. Am J Physiol (1971) 2.05
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods (1993) 1.86
Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology (1998) 1.81
Comparison of microelectrode, DMO, and methylamine methods for measuring intracellular pH. Am J Physiol (1976) 1.80
The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol (1989) 1.78
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Infect Immun (1981) 1.74
pH regulation in barnacle muscle fibers: dependence on intracellular and extracellular pH. Am J Physiol (1979) 1.70
Intracellular pH and distribution of weak acids across cell membranes. A study of D- and L-lactate and of DMO in rat diaphragm. J Physiol (1975) 1.62
Aggregated human immunoglobulin G stabilized by albumin: a standard for immune complex detection. J Immunol Methods (1979) 1.60
T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol (1992) 1.58
A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int (2006) 1.58
The intracellular pH of frog skeletal muscle: its regulation in isotonic solutions. J Physiol (1983) 1.57
Influence of cyclic AMP on intracellular pH regulation and chloride fluxes in barnacle muscle fibers. Nature (1978) 1.56
Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am J Transplant (2009) 1.53
Interaction between human neutrophils and zymosan particles: the role of opsonins and divalent cations. J Immunol (1981) 1.51
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
C3 requirements for formation of alternative pathway C5 convertase. J Immunol (1976) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol (2001) 1.49
The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol (1997) 1.48
Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol (1998) 1.47
Bone marrow IgA and IgA subclass synthesis in ankylosing spondylitis. J Rheumatol (1992) 1.47
Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood (1993) 1.46
The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol (2000) 1.45
Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med (1980) 1.44
Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum (1992) 1.44
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum (2009) 1.40
Surgically created fourth-third cranial nerve communication: temporary success in a child with bilateral third nerve hamartomas. Case report. J Neurosurg (1999) 1.39
Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). J Immunol (1976) 1.38
Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol (1987) 1.38
The role of complement in the binding and degradation of immunoglobulin aggregates by macrophages. J Immunol (1979) 1.36
Enhanced degradation of soluble immunoglobulin aggregates by macrophages in the presence of complement. Immunology (1979) 1.35
Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol (1997) 1.34
The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (1985) 1.34
pH regulation in barnacle muscle fibers: dependence on extracellular sodium and bicarbonate. Am J Physiol (1981) 1.33
Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol (2000) 1.32
Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int (1984) 1.32
Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis (1999) 1.30
IgA- and secretory IgA-opsonized S. aureus induce a respiratory burst and phagocytosis by polymorphonuclear leucocytes. Immunology (1987) 1.30
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29
Regulation of intracellular pH in human neutrophils. J Gen Physiol (1985) 1.29
Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int (1995) 1.29
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost (2006) 1.28
Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol (1995) 1.27
Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol (1984) 1.26
Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J Clin Invest (1991) 1.25
Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis (1994) 1.24
First observation of CP violation in the decays of B(s)0 mesons. Phys Rev Lett (2013) 1.21
Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. J Immunol (1980) 1.21
Normal reference-intervals for 20 biochemical variables in healthy infants, children, and adolescents. Clin Chem (1984) 1.21
Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. J Immunol (1978) 1.21
Presence of circulating macromolecular IgA in patients with hematuria due to primary IgA nephropathy. Am J Med (1983) 1.19
The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother (1996) 1.18
Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum (1994) 1.17
Analysis of lymphoid and dendritic cells in human lymph node, tonsil and spleen. A study using monoclonal and heterologous antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 1.17
Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Immunol (1989) 1.17
Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood (2001) 1.16
Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol (1997) 1.16
Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol (1988) 1.15
Effects of C-1 on the size of soluble immune aggregates and on their processing by macrophages. J Immunol (1979) 1.15
Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol (1996) 1.14
Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. Immunology (1980) 1.14
Spiral CT findings in active and remission phases in patients with Crohn disease. J Comput Assist Tomogr (2001) 1.14
Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J Immunol (1980) 1.13
Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood (1999) 1.13
Clearance of soluble aggregates of human immunoglobulin G in healthy volunteers and chimpanzees. Clin Exp Immunol (1987) 1.12
The role of cellular Fc and C3 receptors on the complement-dependent degradation of stable soluble immunoglobulin aggregates by normal and trypsin-treated peritoneal macrophages. Immunology (1982) 1.12
Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol (2000) 1.12
The buffer value of weak acids and bases: origin of the concept, and first mathematical derivation and application to physico-chemical systems. The work of M. Koppel and K. Spiro (1914). Respir Physiol (1980) 1.12
Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis (1993) 1.12
Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates. Immunology (1982) 1.09
Possible involvement of terminal complement complex in active Heymann nephritis. Kidney Int (1985) 1.09
Selective inhibition of immune complex trapping by follicular dendritic cells with monoclonal antibodies against rat C3. Eur J Immunol (1992) 1.09
Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol (2001) 1.09
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods (1996) 1.08
The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. J Immunol (1977) 1.08
Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb. J Immunol (1982) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol (1998) 1.07
Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol (1999) 1.07
Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology (1996) 1.07